Thursday 18 June 2026

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?

Pharmaceutical
4 July 2022
episode15-big

More on this story...

Pharmaceutical
Is AI patentable?
5 July 2022
Pharmaceutical
Industry spending on AI set to reach $3 billion by 2025
8 July 2022
Pharmaceutical
Elix launches AI drug discovery platform
15 July 2022
Biotechnology
AbCellera and Rallybio link up on antibodies for rare diseases
1 December 2022




More ones to watch >




Today's issue

Curium court decision advances therapy plans for GEP-NETs
Pharmaceutical
Curium court decision advances therapy plans for GEP-NETs
18 June 2026
Biotechnology
FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Pharmaceutical
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Biosimilars
Samsung Bioepis and Organon expand commercialization of Pyzchiva
18 June 2026
Generics
First generic Xofluza clears US FDA ahead of flu season
18 June 2026
Pharmaceutical
Neurizon locks in Elanco supply for ALS hopeful
18 June 2026
Biotechnology
Biogen expands immunology pipeline with RayThera buy
18 June 2026


Company Spotlight

Edgewise Therapeutics
A Boulder, Colorado-based biotech that has sharpened its focus entirely on cardiovascular disease after divesting its muscular dystrophy franchise to Servier, with oral cardiac sarcomere modulator EDG-7500 now its singular Phase III-bound bet in hypertrophic cardiomyopathy.


More Features in Pharmaceutical

Curium court decision advances therapy plans for GEP-NETs
18 June 2026
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Neurizon locks in Elanco supply for ALS hopeful
18 June 2026
F2G and Shionogi set up regulatory push for olorofim after Phase III win
18 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze